{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T16:37:11Z","timestamp":1778431031414,"version":"3.51.4"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Progression-free survival (PFS) is a common primary endpoint in newly diagnosed multiple myeloma (NDMM). Patients with NDMM typically have longer PFS and are more likely to achieve minimal residual disease (MRD) or complete response (CR) compared to patients with relapsed or refractory multiple myeloma. Response-based surrogate endpoints may hold value given the longer follow-up time required to evaluate PFS in NDMM. In this work, systematic literature reviews of Medline, Embase, and Cochrane databases (2010-06\/2020) and relevant congresses (2018\u20132020) were performed to identify randomized clinical trials (RCTs) and real-world studies in NDMM reporting median PFS and objective response. Associations between PFS and each response endpoint were evaluated using Pearson\u2019s product-moment correlation weighted by sample size in each RCT arm. Unadjusted and adjusted weighted linear regression models were applied to estimate the gain in median PFS associated with each response endpoint. Statistically significant correlations were identified for median PFS with overall response rate (ORR; Pearson r = 0.59), CR (r = 0.48), stringent CR (sCR; r = 0.68), and MRD (r = 0.69). The unadjusted models estimated 0.50 (95% CI: 0.36, 0.64; p&lt;0.001), 0.42 (95% CI: 0.25, 0.58; p&lt;0.001), 1.05 (95% CI: 0.58, 1.52; p&lt;0.001), and 0.35 (95% CI: 0.12, 0.58; p = 0.006) months of median PFS gained per point of ORR, CR, sCR, and MRD, respectively. Associations for median PFS remained statistically significant in models adjusted for age and treatment type with ORR (0.35, 95% CI: 0.21, 0.49; p&lt;0.001), and adjusted for age and International Staging System risk stage with CR (0.29, 95% CI: 0.16, 0.41; p&lt;0.001). Due to small sample size, adjusted models could not be constructed for sCR or MRD. Nevertheless, evidence of significant survival benefit (p&lt;0.05) associated with MRD negativity and sCR was identified across real-world studies. These findings provide support for the use of response outcomes as surrogate endpoints to estimate PFS benefit in NDMM.<\/jats:p>","DOI":"10.1371\/journal.pone.0267979","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T17:47:31Z","timestamp":1652377651000},"page":"e0267979","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma"],"prefix":"10.1371","volume":"17","author":[{"given":"Patrick","family":"Daniele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Mamolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph C.","family":"Cappelleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Neuhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihaela","family":"Musat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Forsythe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"issue":"1","key":"pone.0267979.ref001","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"SK Kumar","year":"2017","journal-title":"Nat Rev Dis Primer"},{"key":"pone.0267979.ref002","unstructured":"SEER. Myeloma\u2014Cancer Stat Facts [Internet]. SEER. 2021 [cited 2021 Feb 3]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"issue":"4","key":"pone.0267979.ref003","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjh.12419","article-title":"Readying the minimal residual disease concept in acute myeloid leukaemia for prime time\u2014the American way","volume":"162","author":"P Hokland","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"pone.0267979.ref004","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11899-019-0495-9","article-title":"Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?","volume":"14","author":"SA Holstein","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"pone.0267979.ref005","author":"SK Kumar","year":"2021","journal-title":"NCCN Guidelines Insights: Multiple Myeloma, Version 7.2021"},{"issue":"3","key":"pone.0267979.ref006","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"MA Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"pone.0267979.ref007","unstructured":"Center for Drug Evaluation and Research. Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensure. FDA [Internet]. 2021 Mar 31 [cited 2021 May 18]; Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/table-surrogate-endpoints-were-basis-drug-approval-or-licensure"},{"issue":"10","key":"pone.0267979.ref008","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40273-020-00935-1","article-title":"Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines","volume":"38","author":"B Grigore","year":"2020","journal-title":"PharmacoEconomics"},{"issue":"10","key":"pone.0267979.ref009","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1200\/JCO.2003.99.089","article-title":"Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer","volume":"21","author":"A Di Leo","year":"2003","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"pone.0267979.ref010","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/PPO.0b013e3181be231d","article-title":"Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy","volume":"15","author":"SH Zhuang","year":"2009","journal-title":"Cancer J Sudbury Mass"},{"issue":"9","key":"pone.0267979.ref011","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","article-title":"Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma","volume":"4","author":"SA Holstein","year":"2017","journal-title":"Lancet Haematol"},{"key":"pone.0267979.ref012","article-title":"A Triplet Bortezomib- And Immunomodulator-Based Therapy Before And After Double ASCT Improves Overall Survival Of Newly Diagnosed MM Patients: Final Analysis Of Phase 3 GIMEMA-MMY-3006 Study","author":"P Tacchetti","year":"2018","journal-title":"EHA"},{"issue":"3","key":"pone.0267979.ref013","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000375392","article-title":"Relationship between Treatment Effects on Progression-Free Survival and Overall Survival in Multiple Myeloma: A Systematic Review and Meta-Analysis of Published Clinical Trial Data","volume":"38","author":"S Cartier","year":"2015","journal-title":"Oncol Res Treat"},{"issue":"9","key":"pone.0267979.ref014","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","volume":"6","author":"SZ Usmani","year":"2019","journal-title":"Lancet Haematol"},{"key":"pone.0267979.ref015","article-title":"Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives","author":"R Mina","year":"2020","journal-title":"J Clin Med"},{"issue":"11","key":"pone.0267979.ref016","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1200\/JCO.2000.18.11.2273","article-title":"Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma","volume":"18","author":"G Martinelli","year":"2000","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"pone.0267979.ref017","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"S Kumar","journal-title":"Lancet Oncol"},{"issue":"1","key":"pone.0267979.ref018","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","article-title":"Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis","volume":"20","author":"H Avet-Loiseau","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"23","key":"pone.0267979.ref019","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"NC Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"pone.0267979.ref020","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"MJ Page","year":"2021","journal-title":"BMJ"},{"key":"pone.0267979.ref021","doi-asserted-by":"crossref","DOI":"10.1002\/9780470743386","volume-title":"Introduction to meta-analysis","author":"M Borenstein","year":"2009"},{"key":"pone.0267979.ref022","unstructured":"IQWiG. Validity of surrogate endpoints in oncology [Internet]. 2011 Nov [cited 2021 Jun 15]. Report No.: A10-05. Available from: https:\/\/www.iqwig.de\/download\/a10-05_executive_summary_v1-1_surrogate_endpoints_in_oncology.pdf?rev=185859"},{"issue":"2","key":"pone.0267979.ref023","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"WJ Chng","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"pone.0267979.ref024","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013","volume":"88","author":"JR Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"23","key":"pone.0267979.ref025","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/jnci\/djp369","article-title":"Detecting an overall survival benefit that is derived from progression-free survival","volume":"101","author":"KR Broglio","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"pone.0267979.ref026","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Minimal residual disease predicts superior survival in patients with multiple myeloma: a meta-analysis","volume":"3","author":"NC Munshi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"7","key":"pone.0267979.ref027","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamainternmed.2019.0583","article-title":"An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate","volume":"179","author":"EY Chen","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"9","key":"pone.0267979.ref028","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.7150\/jca.18686","article-title":"Response Rates as Predictors of Overall Survival: A Meta-Analysis of Acute Myeloid Leukemia Trials","volume":"8","author":"SK Agarwal","year":"2017","journal-title":"J Cancer"},{"issue":"8","key":"pone.0267979.ref029","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/annonc\/mdp588","article-title":"Is response rate increment obtained by molecular targeted agents related to survival benefit in the phase III trials of advanced cancer?","volume":"21","author":"K Tsujino","year":"2010","journal-title":"Ann Oncol"},{"issue":"4","key":"pone.0267979.ref030","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.clgc.2013.07.012","article-title":"Surrogate end points and postprogression survival in renal cell carcinoma: an analysis of first-line trials with targeted therapies","volume":"11","author":"F Petrelli","year":"2013","journal-title":"Clin Genitourin Cancer"},{"issue":"8","key":"pone.0267979.ref031","first-page":"994","article-title":"Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib","volume":"4","author":"K Tsujino","year":"2009","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"pone.0267979.ref032","article-title":"Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non\u2013Small Cell Lung Cancer Trials","author":"GM Blumenthal","year":"2017","journal-title":"JAMA Oncol"},{"issue":"11","key":"pone.0267979.ref033","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41416-020-01050-w","article-title":"A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer","volume":"123","author":"K Cooper","year":"2020","journal-title":"Br J Cancer"},{"issue":"8","key":"pone.0267979.ref034","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"NC Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"pone.0267979.ref035","article-title":"CARTITUDE-1: Phase 1b\/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen\u2013Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed\/Refractory Multiple Myeloma","author":"D. Madduri","year":"2020","journal-title":"In ASH"},{"issue":"10","key":"pone.0267979.ref036","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/j.1742-1241.2009.02168.x","article-title":"From the Health Outcomes, Policy, and Economics (HOPE) Collaborative Group. Understanding heterogeneity in meta-analysis: the role of meta-regression","volume":"63","author":"WL Baker","year":"2009","journal-title":"Int J Clin Pract"},{"key":"pone.0267979.ref037","unstructured":"IQWiG. Surrogate Endpoints in Oncology [Internet]. 2011 [cited 2021 May 17]. Available from: https:\/\/www.iqwig.de\/download\/a10-05_executive_summary_v1-1_surrogate_endpoints_in_oncology.pdf?rev=185859"},{"issue":"6","key":"pone.0267979.ref038","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ajh.26166","article-title":"Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review","volume":"96","author":"GR Mohyuddin","year":"2021","journal-title":"Am J Hematol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0267979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T17:47:57Z","timestamp":1652377677000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0267979"}},"subtitle":[],"editor":[{"given":"David","family":"Dingli","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0267979","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]}}}